Tesamorelin, Cognition and the CNS: GHRH Analogues in HIV Neurocognitive and Aging Research

RESEARCH · TESAMORELIN · COGNITION & CNS

Tesamorelin, Cognition and the CNS: GHRH Analogues in HIV Neurocognitive and Aging Research

Tesamorelin is a stabilised analogue of growth hormone–releasing hormone (GHRH) best known for reducing visceral adipose tissue in antiretroviral-treated people with HIV [1]. Our earlier articles cover the GHRH-analogue research overview and visceral adipose and NAFLD/liver-fat findings. This article turns to the central nervous system: what randomised and related studies report about cognition, brain chemistry and HIV-associated neurocognitive impairment. PurixLab’s Tesamorelin 5mg is a research material for laboratory research use only.

Why the GHRH–GH–IGF-1 axis is linked to the brain

GHRH, growth hormone and IGF-1 have potent effects on brain function; their circulating activity declines with age, and investigators have long asked whether restoring the axis could influence cognition in aging or mild cognitive impairment (MCI) [2,3]. In people with HIV who are virally suppressed, abdominal obesity has been linked to neurocognitive impairment, with proposed contributions from visceral adiposity, inflammation and reduced IGF-1 — a rationale for testing whether tesamorelin’s visceral-fat and IGF-1 effects might also change cognitive scores [4].

GHRH analogues in healthy aging and MCI

An earlier controlled study of daily GHRH versus placebo for 6 months in 89 healthy older adults (mean age 68.0 ± 0.7 years) reported improved performance on several WAIS-R and related tasks, independent of gender, estrogen status or baseline cognitive capacity [3]. Baker and colleagues then ran a randomised, double-blind, placebo-controlled trial of tesamorelin versus placebo for 20 weeks in 152 adults aged 55 to 87 years (mean 68), including 66 with MCI; 137 completed the protocol [2]. Intent-to-treat analysis showed a favourable GHRH effect on cognition (P = .03), comparable in MCI and healthy older adults, with a stronger signal among completers (P = .002); executive function improved (P = .005) and verbal memory showed a trend (P = .08) [2]. IGF-1 rose by 117% within the physiological range, and percent body fat fell by 7.4% [2]. A Nature Reviews commentary summarised the Baker trial as evidence that tesamorelin can improve cognitive function [5].

A companion magnetic-resonance spectroscopy study in the same programme examined brain γ-aminobutyric acid (GABA) levels in MCI and healthy aging after GHRH exposure, linking the cognitive programme to a neurotransmitter readout [6]. Later, Winston and colleagues analysed plasma neuronally derived exosomes from participants in a 20-week GHRH trial: Aβ1-42 was higher and several synaptic cargo proteins (neurogranin, synaptophysin, synaptotagmin, synaptopodin) lower in MCI than in cognitively normal controls, independent of GHRH treatment, with only moderate accuracy for distinguishing placebo-treated from GHRH-treated MCI on selected synaptic markers [7].

Tesamorelin and HIV-associated neurocognitive impairment

Ellis and colleagues tested the obesity–cognition hypothesis directly in a 6-month phase 2 randomised open-label trial of tesamorelin versus standard of care in virally suppressed people with HIV and abdominal obesity (elevated waist circumference), randomised 3:2 [4]. The primary outcome was change in neurocognitive performance at 6 months. The tesamorelin arm showed a trend toward improvement (mean change 0.146; 95% CI −0.002 to 0.294; P = .060) while standard of care did not (0.103; 95% CI −0.095 to 0.301; P = .295), but the between-group difference was not significant (P = .673) [4]. Waist circumference fell more with tesamorelin (median difference −2.7 cm; P = .015), and IGF-1 rose without correlating with the summary regression change score or waist change [4]. The authors conclude that, recognising limited power and the absence of a placebo arm, short-term abdominal-obesity reduction with tesamorelin did not clearly benefit neurocognitive impairment [4].

Low-level exposure and connectivity pilots

A double-blind, placebo-controlled pilot in 22 adults with cognition ranging from normal to MCI compared 10 weeks of low-level tesamorelin with placebo and found no significant groupwise changes on standard cognitive, morphometric or functional-connectivity measures; machine-learning models flagged possible treatment-related differences in regions including the right anterior cingulate and left superior frontal occipital fasciculus [8]. That study is hypothesis-generating rather than confirmatory.

What remains open

  • HIV trial null on the primary. Waist circumference moved, but cognitive change did not differ from standard of care [4].
  • Aging/MCI signal is older and GHRH-class. The strongest cognitive gains come from Baker 2012 and related GHRH work, not from a modern HIV neurocognitive programme [2,3].
  • Biomarkers vs cognition. Neuronal exosome cargo distinguishes MCI from controls better than it tracks GHRH assignment [7].
  • VAT biology is clearer than CNS biology. Pooled phase 3 HIV lipodystrophy data show a −15.4% visceral adipose treatment effect and a large IGF-I rise, without answering cognition [1].

Tesamorelin 5mg at PurixLab

Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tesamorelin 5mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713 · doi:10.1210/jc.2010-0490
  2. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-9. PubMed 22869065 · PMC3764914 · doi:10.1001/archneurol.2012.1970
  3. Vitiello MV, Moe KE, Merriam GR, et al. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-23. PubMed 16399214 · doi:10.1016/j.neurobiolaging.2005.01.010
  4. Ellis RJ, Vaida F, Hu K, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025;231(5):1230-1238. PubMed 39813152 · doi:10.1093/infdis/jiaf012
  5. McLarnon A. Neuroendocrinology: Tesamorelin can improve cognitive function. Nat Rev Endocrinol. 2012;8(10):568. PubMed 22926095 · doi:10.1038/nrendo.2012.151
  6. Friedman SD, Baker LD, Borson S, et al. Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA Neurol. 2013;70(7):883-90. PubMed 23689947 · PMC3764915 · doi:10.1001/jamaneurol.2013.1425
  7. Winston CN, Goetzl EJ, Baker LD, et al. Growth Hormone-Releasing Hormone Modulation of Neuronal Exosome Biomarkers in Mild Cognitive Impairment. J Alzheimers Dis. 2018;66(3):971-981. PubMed 30372675 · PMC6487872 · doi:10.3233/JAD-180302
  8. Stewart CE, French KP, Wright TJ, et al. The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. eNeurologicalSci. 2026;44:100616. PubMed 42382101 · PMC13316082 · doi:10.1016/j.ensci.2026.100616

Leave a Comment

Your email address will not be published. Required fields are marked *